Literature DB >> 1053931

Chronic granulocytic leukaemia: effect of elective splenectomy on the course of disease.

A S Spiers, A F Baikie, D A Galton, H G Richards, E Wiltshaw, J M Goldman, D Catovsky, J Spencer, R Peto.   

Abstract

Conventional treatment by drugs or irradiation produces little prolongation of life in patients with chronic granulocytic leukaemia (C.G.L.) because the onset of metamorphosis of the disease from a chronic to an acute or subacute leukaemic process is not substantially postponed. Isolated clinical observations as well as both cytogenetic and cytokinetic evidence suggest that the spleen may play a special though not exclusive role in the development of undifferentiated cell clones which lead to metamorphosis of C.G.L. The results of a study of elective splenectomy during the chronic phase of the disease are reported. Twenty-six patients with C.G.L. underwent splenectomy during clinical remission of their disease, and there were no deaths after the operation. Twenty-one patients were alive at the time of writing, two of them eight years after splenectomy. Five cases of metamorphosis of C.G.L. to a refractory phase occurred whereas 10 would have been expected, a significant difference. After the onset of metamorphosis the quality of life was better in splenectomized than in non-splenectomized patients. These results show that splenectomy is a reasonable and safe procedure in C.G.L., and its apparently beneficial effects on prognosis justify a larger controlled clinical trial.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1053931      PMCID: PMC1672174          DOI: 10.1136/bmj.1.5951.175

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  17 in total

1.  Cytogenetic evidence for splenic origin of blastic transformation in chronic myeloid leukaemia.

Authors:  F Mitelman; L Brandt; P G Nilsson
Journal:  Scand J Haematol       Date:  1974

2.  Survival in chronic myelogenous leukemia: influence of treatment and extent of disease at diagnosis.

Authors:  S Monfardini; T Gee; J Fried; B Clarkson
Journal:  Cancer       Date:  1973-03       Impact factor: 6.860

3.  Splenectomy and leucopheresis in chronic granulocytic leukaemia.

Authors:  A S Spiers; M H Tattersall; D A Galton
Journal:  Br Med J       Date:  1973-06-09

Review 4.  Chemotherapy of chronic myelocytic leukemia.

Authors:  D A Galton
Journal:  Semin Hematol       Date:  1969-10       Impact factor: 3.851

5.  The role of splenectomy in malignant lymphoma and leukemia.

Authors:  W R Meeker; J M dePerio; J T Grace; L Stutzman; A Mittelman
Journal:  Surg Clin North Am       Date:  1967-10       Impact factor: 2.741

6.  Myelofibrosis in chronic granulocytic leukemia.

Authors:  H R Gralnick; J Harbor; C Vogel
Journal:  Blood       Date:  1971-02       Impact factor: 22.113

7.  [Survival for 7 years after splenectomy in chronic myelocytic leukemia].

Authors:  H Dubois-Ferrière; J C Rudler
Journal:  Schweiz Med Wochenschr       Date:  1967-02-11

Review 8.  Progress in the leukemias.

Authors:  D A Galton; A S Spiers
Journal:  Prog Hematol       Date:  1971

9.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

10.  Persistent post-splenectomy thrombocytosis and thrombo-embolism: a consequence of continuing anaemia.

Authors:  J Hirsh; J V Dacie
Journal:  Br J Haematol       Date:  1966-01       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.